Gossamer Bio (GOSS) Net Cash Flow (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Net Cash Flow of $3.4 million for Q1 2026, up 119.8% year-over-year from $1.5 million in Q1 2025, and down 88.2% quarter-over-quarter from $28.8 million in Q4 2025.
Gossamer Bio (GOSS) Net Cash Flow (2018 - 2026) Analysis & Trends
Gossamer Bio's Net Cash Flow history runs 9 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 119.8% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.1 million (up 221.85% YoY), while the FY2025 annual figure was -$8.5 million, down 160.3% from the prior year.
- Net Cash Flow for Q1 2026 stood at $3.4 million, down from $28.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $59.6 million in Q3 2022, with the low at -$58.5 million in Q3 2024.
- The 5-year median for Net Cash Flow is -$17.2 million (2025), against an average of -$8.4 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 270.18% in 2024, then plunged 351.73% in 2025.
- Gossamer Bio's Net Cash Flow stood at -$42.1 million in 2022, then declined by 20.3% to -$50.7 million in 2023, then jumped by 134.99% to $17.7 million in 2024, then jumped by 62.37% to $28.8 million in 2025, then plunged by 88.2% to $3.4 million in 2026.
- Business Quant data shows GOSS's Net Cash Flow at $3.4 million in Q1 2026, $28.8 million in Q4 2025, and -$17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | 132,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132,000.00 |
| Jun 30, 2026 | 132,000.00 |
| Mar 31, 2026 | 3.40 Mn |
| Mar 31, 2026 | 3.40 Mn |
| Dec 31, 2025 | 28.80 Mn |
| Dec 31, 2025 | 28.80 Mn |
| Sep 30, 2025 | -17.28 Mn |
| Sep 30, 2025 | -17.28 Mn |
| Jun 30, 2025 | -2.84 Mn |
| Jun 30, 2025 | -2.84 Mn |
| Mar 31, 2025 | -17.16 Mn |
| Mar 31, 2025 | -17.16 Mn |
| Dec 31, 2024 | 17.74 Mn |
| Dec 31, 2024 | 17.74 Mn |
| Sep 30, 2024 | -58.51 Mn |
| Sep 30, 2024 | -58.51 Mn |
| Jun 30, 2024 | 48.02 Mn |
| Jun 30, 2024 | 48.02 Mn |
| Mar 31, 2024 | 6.82 Mn |
| Mar 31, 2024 | 6.82 Mn |